| [1] | Steinmetz J. D., Culbreth G. T., Haile L. M., et al. (2023). Global, regional, and national burden of osteoarthritis, 1990–2020 and projections to 2050: A systematic analysis for the Global Burden of Disease Study 2021. Lancet Rheumatol. 5:e508−e522. DOI:10.1016/S2665-9913(23)00163-7 |
| [2] | Anekwe C. V., Jarrell A. R., Townsend M. J., et al. (2020). Socioeconomics of obesity. Curr. Obes. Rep. 9:272−279. DOI:10.1007/s13679-020-00398-7 |
| [3] | Chen L., Zheng J. J. Y., Li G., et al. (2020). Pathogenesis and clinical management of obesity-related knee osteoarthritis: Impact of mechanical loading. J. Orthop. Translat. 24:66−75. DOI:10.1016/j.jot.2020.05.001 |
| [4] | Bliddal H., Bays H., Czernichow S., et al. (2024). Once-weekly Semaglutide in persons with obesity and knee osteoarthritis. N. Engl. J. Med. 391:1573−1583. DOI:10.1056/NEJMoa2403664 |
| [5] | Zhu H., Zhou L., Wang Q., et al. (2023). Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: Findings from the Shanghai Osteoarthritis Cohort. Ann. Rheum. Dis. 82:1218−1226. DOI:10.1136/ard-2023-223845 |
| Zhou L., He S., Li C., et al. (2025). Two birds with one stone — Semaglutide's impacts on obesity and knee osteoarthritis: From weight loss to pain relief. The Innovation Medicine 3:100110. https://doi.org/10.59717/j.xinn-med.2025.100110 |
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
Two birds with one stone—the dual benefits of Semaglutide in addressing obesity and OA simultaneously and future possible follow-up research.